Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 33.36M | 21.16M | 20.68M | 21.94M | 21.61M |
Gross Profit | 24.10M | 17.09M | 16.68M | 18.26M | 18.55M |
EBITDA | 11.87M | 11.53M | 12.04M | 13.66M | 13.40M |
Net Income | 11.54M | 20.38M | 26.64M | 7.76M | 4.55M |
Balance Sheet | |||||
Total Assets | 162.51M | 86.03M | 73.78M | 51.65M | 44.28M |
Cash, Cash Equivalents and Short-Term Investments | 17.84M | 39.83M | 28.84M | 20.55M | 9.14M |
Total Debt | 40.58M | 353.00K | 428.00K | 516.00K | 1.85M |
Total Liabilities | 60.17M | 5.51M | 9.70M | 12.75M | 11.63M |
Stockholders Equity | 102.34M | 80.52M | 64.08M | 38.90M | 32.64M |
Cash Flow | |||||
Free Cash Flow | 19.50M | 15.98M | 10.49M | 13.81M | 10.93M |
Operating Cash Flow | 19.55M | 16.00M | 10.57M | 13.81M | 11.69M |
Investing Cash Flow | -80.04M | -144.00K | -81.00K | 0.00 | -760.00K |
Financing Cash Flow | 39.30M | -5.24M | -1.91M | -2.47M | -8.13M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | C$321.31M | 24.97 | 9.69% | ― | 84.83% | -58.69% | |
71 Outperform | $246.35M | 17.68 | 4.76% | ― | 26.93% | ― | |
71 Outperform | C$102.26M | 24.69 | 5.27% | ― | -3.82% | -50.36% | |
65 Neutral | C$580.82M | 54.10 | 1.41% | ― | 12.21% | ― | |
60 Neutral | HK$15.27B | 5.80 | -7.43% | 4.22% | 11.60% | -21.06% | |
56 Neutral | C$151.16M | ― | -23.05% | ― | -3.73% | 32.70% | |
49 Neutral | $149.44M | ― | ― | 16.23% | 85.76% |
Cipher Pharmaceuticals announced the successful results of its annual and special meeting of shareholders, where all proposed matters were approved by a majority vote. Key approvals included the election of director nominees, the re-appointment of RSM Canada LLP as auditor, and the resolution concerning unallocated shares under the company’s share purchase plan. Approximately 50.9% of total shares were represented at the meeting, indicating strong shareholder engagement.
The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.
Cipher Pharmaceuticals reported a significant financial performance in the first quarter of 2025, with total revenue increasing by 105% to $12.0 million compared to the previous year. The company’s Canadian product portfolio saw a 41% revenue increase, and Natroba™ sales contributed $6.7 million. The company also announced a $15 million debt repayment, reducing its revolving credit facility balance, and highlighted strategic moves such as the preferred status of Natroba™ in Illinois Medicaid and a share repurchase program, indicating a strong financial position and strategic growth opportunities.
Cipher Pharmaceuticals announced its financial results for the first quarter of 2025 will be released on May 8, 2025, followed by a conference call on May 9, 2025, to discuss the results and corporate developments. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor relations.
Cipher Pharmaceuticals announced that its product Natroba™ has been granted preferred drug status on Illinois’ Medicaid Preferred Drug Listing for the treatment of scabies and head lice, while its competitor, Permethrin 5%, has been downgraded. This decision is expected to influence prescribing habits, potentially benefiting Cipher’s market position. The company sees this as a significant growth opportunity and is in discussions with other states to expand Natroba’s preferred status, addressing the global issue of lice resistance to Permethrin.